Bioatla (BCAB) Q3 2024 earnings summary

Executive summary

• Reported significant clinical progress across CAB pipeline, including positive data in head and neck cancer, melanoma, and non-small cell lung cancer, with two registrational trials planned for 2025.

• Received FDA Fast Track designation for ozuriftamab vedotin in refractory head and neck cancer and Orphan Drug Designation for mecbotamab vedotin.

• Announced a worldwide license agreement for the preclinical CAB-Nectin-4 bispecific T cell engager, generating $11 million upfront and eligibility for up to $133.5 million in milestones and royalties.

• Maintains focus on advancing ROR2 and CTLA-4 assets toward pivotal registrational trials in 2025, with ROR2 ahead in timing.

• Ongoing discussions for strategic collaborations on Phase 2 assets.

Financial highlights

• Q3 2024 research and development expenses were $16.4 million, down from $28.4 million in Q3 2023, due to program prioritization and trial completions.

• General and administrative expenses decreased to $5.9 million from $6.6 million year-over-year, mainly due to lower stock-based compensation and insurance costs.

• Recognized $11 million in collaboration revenue from a license agreement; net loss for Q3 2024 was $10.6 million, improved from $33.3 million in Q3 2023.

• Cash and cash equivalents stood at $56.5 million as of September 30, 2024, expected to fund operations into early 2026.

• Net cash used in operating activities for the nine months ended September 30, 2024, was $55.2 million, down from $74.1 million in the same period in 2023.

Outlook and guidance

• Expects current cash to support completion of dose optimization for CAB-ROR2 and CAB-CTLA-4 and position both for registrational trials.

• Anticipates initiating pivotal trials for ROR2 and CTLA-4 programs in 2025, with ROR2 ahead in timing.

• Maintains guidance for a near-term strategic collaboration for at least one phase II asset.

• Additional capital will be needed for long-term development and commercialization.

• R&D expenses are expected to decrease in the near term as certain clinical trials complete enrollment, but may rise again with new trial initiations.